comprehensive -WSS

comprehensive

author：focus 2025-09-30 20:47:16 - browse：13539

Adobe

WASHINGTON — The federal government increasingly is scrutinizing Chinese businesses and their interactions with American companies, including in the biotech sector. Chinese biotechnology companies, the thinking goes, could threaten national security by giving the Chinese government access to the genetic and health information of Americans.

Just Wednesday, President Biden issued an executive order aimed at keeping sensitive data, including Americans’ genetic information, out of the hands of adversaries.

But American biotech companies worry they could become collateral damage if the government sloppily targets sanctions. They’re pushing back against legislation that would bar biotech companies from working with some Chinese companies, especially as the government takes aim at WuXi, a Chinese company considered a crucial partner for discovering, testing, and making medicines that has worked with such brands as Pfizer, AstraZeneca, and GSK.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Some of the ways extreme heat will change life as we know it

WSS

House GOP releases memo on Hunter Biden foreign business dealings, reviving old claims

Virtual care provider acquires bankrupt Pear's prescription apps

The history of OxyContin, told through Purdue Pharma documents

Prime Medicine, Myeloid Therapeutics clash over genome

Hospitals owned by private equity see complications spike 25%

House GOP releases memo on Hunter Biden foreign business dealings, reviving old claims

entertainment

comprehensive

focus

As demand for Covid shots wanes, Moderna seeks its next success

Humana’s Medicare Advantage lawsuit should be tossed, DOJ says

The cancer drug shortage isn’t new — and neither are the solutions

Faced with fears of OxyContin misuse, sales reps touted its safety

United colonoscopy coverage change 'may cost lives,' doctors say

Genentech weighs delaying cancer therapy after drug pricing law

Bright Health sells Medicare Advantage business to Molina

Humana’s Medicare Advantage lawsuit should be tossed, DOJ says

Medicare proposal to cover medical devices draws a mixed reaction

Why health records don't always know when patients are dead

entertainment

David Ricks of Eli Lilly: best biopharma CEO of 2023

Timeline: Special counsel's investigation into Trump's handling of classified documents

Pharma budget tightening trickles down to Doximity

Medicare drug price negotiation hasn't dried up venture capital

Editas, Vertex strike deal on CRISPR

Humana’s Medicare Advantage lawsuit should be tossed, DOJ says

entertainment

knowledge

entertainment

focus